Table 3.

Demographics and chart review of patients who developed corneal epithelial changes

	Case	Drug	Sex	Age	Diagnosis	Corneal Features	Duration of chemotherapy (day)	Interval 1 (day)	Interval 2 (day)	Visual acuity before chemotherapy (log MAR)		Lowest visual acuity after chemothearpy (log MAR)		Highest visual acuity after end of therapy (log MAR)		Corneal clearance
										OD	OS	OD	OS	OD	OS
EGFR inhibitor (Tyrosine Kinase Inhibitor)	1	Vandetanib	2	30–39	NSCLC	Vortex Keratopathy	284	91	Deceased	0	0	0	0	0	0	N/A
	2		2	60–69	NSCLC		390	395	F/u loss	0.097	0.097	0.301	0.155	0.097	0.097	partial
	3		2	70–79	NSCLC		253	252	230	0.155	0.155	0.222	0.301	0.222	0.155	total
	4	Osimertinib	2	50–59	NSCLC		Ongoing	196	Ongoing	0	0	0.155	0.155	N/A	N/A	N/A
	5	ABT-414	1	50–59	Glioblastoma		59	35	59	0	1	1.222	2	0.699	0.523	partial
	6		2	70–79	Glioblastoma		231	49	141	0.046	0.301	0.523	0.523	0	0.097	total
	7		2	50–59	Glioblastoma		347	23	181	0	0	0.523	0.301	0	0	total
	8		1	40–49	Glioblastoma		111	22	79	0	0	0.301	0.222	0	0	total
	9		2	60–69	Glioblastoma		14	22	149	0	0	0.301	0.699	0	0	total
FGFR inhibitor	10	ASP5878	2	40–49	HCC	Corneal epithelial changes mimicking dysmaturation	195	55	93	0	0	0.301	0.155	0	0	total
	11	FPA144	2	40–49	Gastric cancer		459	73	218	0	0	0.046	0.398	0	0	total
	12		2	60–69	Gastric cancer		70	68	F/u loss	0	0	0.155	0.046	0.097	0.046	partial

EGFR epidermal growth factor receptor, FGFR fibroblast growth factor receptor, NSCLC Non-small cell lung cancer, HCC Hepatocellular carcinoma, Interval 1 Interval between start of chemotherapy and diagnosis of corneal change (day), Interval 2 Interval between end of chemotherapy and corneal recovery (day), OD Oculus Dextra (right eye), OS Oculus Sinistra (left eye), logMAR logarithm of minimal angle of resolution units, N/A Not applicable